Survival of cervical cancer patients at Moi teaching and Referral Hospital, Eldoret in western Kenya.
Cervical cancer
Kenya
Survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
received:
12
10
2022
accepted:
10
10
2023
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
Cervical cancer is a major health burden and the second most common cancer after breast cancer among women in Kenya. Worldwide cervical cancer constitutes 3.1% of all cancer cases. Mortality rates are greatest among the low-income countries because of lack of awareness, screening and early-detection programs and adequate treatment facilities. The main aim was to estimate survival and determine survival predictors of women with cervical cancer and limited resources in western Kenya. Retrospective charts review of women diagnosed with cervical cancer and follow-up for two years from the date of the histologic diagnosis. The outcome of interest was death or survival at two years. Kaplan Meier estimates of survival, log-rank test and Cox proportional hazards regression were used in the survival analysis. One hundred and sixty-two (162) participants were included in the review. The median duration was 0.8 (interquartile range (IQR) 0.3, 1.6) years. The mean age at diagnosis was 50.6 years (SD12.5). The mean parity was 5.9 (SD 2.6). Fifty percent (50%) did not have health insurance. Twenty six percent (26%) used hormonal contraceptives, 25.9% were HIV positive and 70% of them were on anti-retroviral treatment. The participants were followed up for 152.6 person years. Of the 162 women in the study, 70 (43.2%) died giving an overall incidence rate (IR) of 45.9 deaths per 100 person years of follow up. The hazard ratios were better for the patients who survived (0.44 vs 0.88, p-value < 0.001), those who had medical insurance (0.70 vs 0.48, p-value = 0.007) and those with early stage at diagnosis (0.88 vs 0.39, p-value < 0.001). Participants who were diagnosed at late stage of the disease according to the International Federation of Gynecology and Obstetrics staging for cervical cancer (FIGO stage 2B-4B) had more than eight times increased hazard of death compared to those who were diagnosed at early stage (1-2A): Hazard Ratio: 8.01 (95% CI 3.65, 17.57). Similarly, those who underwent surgical management had 84% reduced hazard of mortality compared to those who were referred for other modes of care: HR: 0.16 (95% CI: 0.07, 0.38). Majority of the participants were diagnosed late after presenting with symptoms. The 1 and 2-year survival probability after diagnosis of cervical cancer was 57% AND 45% respectively. It is imperative that women present early since surgery gives better prognosis or better still screening of all women prioritized.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer is a major health burden and the second most common cancer after breast cancer among women in Kenya. Worldwide cervical cancer constitutes 3.1% of all cancer cases. Mortality rates are greatest among the low-income countries because of lack of awareness, screening and early-detection programs and adequate treatment facilities. The main aim was to estimate survival and determine survival predictors of women with cervical cancer and limited resources in western Kenya.
METHODS
METHODS
Retrospective charts review of women diagnosed with cervical cancer and follow-up for two years from the date of the histologic diagnosis. The outcome of interest was death or survival at two years. Kaplan Meier estimates of survival, log-rank test and Cox proportional hazards regression were used in the survival analysis.
RESULTS
RESULTS
One hundred and sixty-two (162) participants were included in the review. The median duration was 0.8 (interquartile range (IQR) 0.3, 1.6) years. The mean age at diagnosis was 50.6 years (SD12.5). The mean parity was 5.9 (SD 2.6). Fifty percent (50%) did not have health insurance. Twenty six percent (26%) used hormonal contraceptives, 25.9% were HIV positive and 70% of them were on anti-retroviral treatment. The participants were followed up for 152.6 person years. Of the 162 women in the study, 70 (43.2%) died giving an overall incidence rate (IR) of 45.9 deaths per 100 person years of follow up. The hazard ratios were better for the patients who survived (0.44 vs 0.88, p-value < 0.001), those who had medical insurance (0.70 vs 0.48, p-value = 0.007) and those with early stage at diagnosis (0.88 vs 0.39, p-value < 0.001). Participants who were diagnosed at late stage of the disease according to the International Federation of Gynecology and Obstetrics staging for cervical cancer (FIGO stage 2B-4B) had more than eight times increased hazard of death compared to those who were diagnosed at early stage (1-2A): Hazard Ratio: 8.01 (95% CI 3.65, 17.57). Similarly, those who underwent surgical management had 84% reduced hazard of mortality compared to those who were referred for other modes of care: HR: 0.16 (95% CI: 0.07, 0.38).
CONCLUSION
CONCLUSIONS
Majority of the participants were diagnosed late after presenting with symptoms. The 1 and 2-year survival probability after diagnosis of cervical cancer was 57% AND 45% respectively. It is imperative that women present early since surgery gives better prognosis or better still screening of all women prioritized.
Identifiants
pubmed: 37957644
doi: 10.1186/s12885-023-11506-w
pii: 10.1186/s12885-023-11506-w
pmc: PMC10644535
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1104Informations de copyright
© 2023. The Author(s).
Références
AIDS. 2017 Feb 20;31(4):523-531
pubmed: 28060014
Psychooncology. 2001 Nov-Dec;10(6):469-78
pubmed: 11747059
J Clin Oncol. 2016 Nov 1;34(31):3749-3757
pubmed: 27573661
PLoS One. 2017 Jul 21;12(7):e0181156
pubmed: 28732037
Gynecol Oncol Rep. 2017 Jul 21;21:101-108
pubmed: 28819634
Afr Health Sci. 2011 Mar;11(1):58-64
pubmed: 21572858
IARC Sci Publ. 2011;(162):7-13
pubmed: 21675401
Best Pract Res Clin Obstet Gynaecol. 2005 Apr;19(2):269-76
pubmed: 15778115
Front Oncol. 2016 Jun 28;6:160
pubmed: 27446806
Br J Cancer. 2005 May 9;92(9):1808-12
pubmed: 15827554
J Epidemiol Community Health. 2011 Jun;65(6):477-82
pubmed: 21138896
Cancer Causes Control. 2009 May;20(4):417-35
pubmed: 19002764
Lancet. 2007 Nov 10;370(9599):1609-21
pubmed: 17993361
Clin Ther. 2016 Mar;38(3):459-66
pubmed: 26899314
Br J Cancer. 2009 Dec 3;101 Suppl 2:S92-S101
pubmed: 19956172
Int J Cancer. 2004 Mar 20;109(2):274-7
pubmed: 14750180
Br J Cancer. 2009 Apr 7;100(7):1191-7
pubmed: 19277042
Infect Agent Cancer. 2016 Mar 24;11:15
pubmed: 27014366
Anticancer Res. 2014 Sep;34(9):5147-51
pubmed: 25202106
Pan Afr Med J. 2014 Oct 31;19:234
pubmed: 25838862
East Afr Med J. 2001 Feb;78(2):55-9
pubmed: 11682945
Br J Cancer. 2016 Feb 2;114(3):334-9
pubmed: 26794277
BMC Womens Health. 2017 Sep 29;17(1):91
pubmed: 28962557